Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06369155
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-12
Brief Title:
Azenosertib in Uterine Serous Carcinoma Biomarker Study
Sponsor:
Joyce Liu MD
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Biomarker Study of the Wee1 Inhibitor Azenosertib ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma
The name of the study drug involved in this study is
-Azenosertib a type of Wee1 inhibitor
The name of the study drug involved in this study is
-Azenosertib a type of Wee1 inhibitor
Detailed Description:
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma Azenosertib has been tested as a treatment for other diseases and has shown to stop cancer cell growth
The US Food and Drug Administration FDA has not approved Azenosertib as a treatment for recurrent uterine serous carcinoma
This research study involves screening for eligibility study treatment visits X-rays Computerized Tomography CT scans Magnetic Resonance Imaging MRI scans Positron Emission Tomography CT PET-CT scans Meta-iodobenzylguanidine MIBG scans Fluorodeoxyglucose Positron Emission Tomography FDG-PET scans Electrocardiograms EKGs tumor biopsies and blood tests
It is expected that about 25 people will take part in this research study
Zentalis Pharmaceuticals is supporting this research study by providing the study drug Azenosertib
The US Food and Drug Administration FDA has not approved Azenosertib as a treatment for recurrent uterine serous carcinoma
This research study involves screening for eligibility study treatment visits X-rays Computerized Tomography CT scans Magnetic Resonance Imaging MRI scans Positron Emission Tomography CT PET-CT scans Meta-iodobenzylguanidine MIBG scans Fluorodeoxyglucose Positron Emission Tomography FDG-PET scans Electrocardiograms EKGs tumor biopsies and blood tests
It is expected that about 25 people will take part in this research study
Zentalis Pharmaceuticals is supporting this research study by providing the study drug Azenosertib
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None